Works by Kanazu, Masaki

Results: 28

Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR‐TKI Administration Using Droplet Digital PCR in Non‐small‐cell Lung Cancer With EGFR Mutation.

Published in:

Cancer Diagnosis & Prognosis, 2025, v. 5, n. 3, p. 285, doi. 10.21873/cdp.10441

By:

KOICHI OGAWA;
HIROYASU KANEDA;
YASUHIRO KOH;
YOSHIYA MATSUMOTO;
KENJI SAWA;
MOTOHIRO TAMIYA;
NOBUHISA ISHIKAWA;
KENICHI MINAMI;
HIDEKAZU SUZUKI;
YOSUKE EGUCHI;
MASAKI KANAZU;
YUKI SATO;
TOMOYA KAWAGUCHI

Publication type:

Article

Clinical benefit of platinum doublet combination therapy in older adults with advanced non‐small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.

Published in:

Thoracic Cancer, 2023, v. 14, n. 17, p. 1597, doi. 10.1111/1759-7714.14904

By:

Shimokawa, Mototsugu;
Kanazu, Masaki;
Saito, Ryusei;
Mori, Masahide;
Tamura, Atsuhisa;
Okano, Yoshio;
Fujita, Yuka;
Endo, Takeo;
Motegi, Mitsuru;
Takata, Shohei;
Kita, Toshiyuki;
Sukoh, Noriaki;
Mizuki, Fumitaka;
Takenoyama, Mitsuhiro;
Atagi, Shinji

Publication type:

Article

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01).

Published in:

Thoracic Cancer, 2023, v. 14, n. 2, p. 168, doi. 10.1111/1759-7714.14729

By:

Uematsu, Shinya;
Kitazono, Satoru;
Tanaka, Hisashi;
Saito, Ryota;
Kawashima, Yosuke;
Ohyanagi, Fumiyoshi;
Tozuka, Takehiro;
Ryosuke, Tsugitomi;
Sakatani, Toshio;
Horiike, Atsushi;
Yoshizawa, Takahiro;
Saiki, Masafumi;
Tambo, Yuichi;
Koyama, Junji;
Kanazu, Masaki;
Kudo, Keita;
Tsuchiya‐Kawano, Yuko;
Yanagitani, Noriko;
Nishio, Makoto

Publication type:

Article

Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study

Published in:

Thoracic Cancer, 2022, v. 13, n. 17, p. 2450, doi. 10.1111/1759-7714.14576

By:

Akazawa, Yuki;
Yoshikawa, Aki;
Kanazu, Masaki;
Yano, Yukihiro;
Yamaguchi, Toshihiko;
Mori, Masahide

Publication type:

Article

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

Published in:

Thoracic Cancer, 2021, v. 12, n. 12, p. 1935, doi. 10.1111/1759-7714.13948

By:

Kuge, Tomoki;
Okabe, Fukuko;
Yamamoto, Yuji;
Ishijima, Mikako;
Uenami, Takeshi;
Kanazu, Masaki;
Akazawa, Yuki;
Yano, Yukihiro;
Yamaguchi, Toshihiko;
Mori, Masahide

Publication type:

Article

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.

Published in:

Thoracic Cancer, 2021, v. 12, n. 9, p. 1441, doi. 10.1111/1759-7714.13920

By:

Hara, Reina;
Kanazu, Masaki;
Iwai, Ami;
Kuge, Tomoki;
Ishijima, Mikako;
Uenami, Takeshi;
Akazawa, Yuki;
Yano, Yukihiro;
Yamaguchi, Toshihiko;
Mori, Masahide

Publication type:

Article

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.

Published in:

Thoracic Cancer, 2021, v. 12, n. 1, p. 90, doi. 10.1111/1759-7714.13718

By:

Kanazu, Masaki;
Mori, Masahide;
Kimura, Madoka;
Nishino, Kazumi;
Shiroyama, Takayuki;
Nagatomo, Izumi;
Ihara, Shoichi;
Komuta, Kiyoshi;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Kumagai, Toru;
Imamura, Fumio

Publication type:

Article

Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study.

Published in:

Thoracic Cancer, 2020, v. 11, n. 11, p. 3317, doi. 10.1111/1759-7714.13675

By:

Yamamoto, Yuji;
Yano, Yukihiro;
Kuge, Tomoki;
Okabe, Fukuko;
Ishijima, Mikako;
Uenami, Takeshi;
Kanazu, Masaki;
Akazawa, Yuki;
Yamaguchi, Toshihiko;
Mori, Masahide

Publication type:

Article

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report.

Published in:

Thoracic Cancer, 2019, v. 10, n. 5, p. 1276, doi. 10.1111/1759-7714.13065

By:

Edahiro, Ryuya;
Ishijima, Mikako;
Kurebe, Hiroyuki;
Nishida, Kohei;
Uenami, Takeshi;
Kanazu, Masaki;
Akazawa, Yuki;
Yano, Yukihiro;
Mori, Masahide

Publication type:

Article

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series.

Published in:

Thoracic Cancer, 2018, v. 9, n. 12, p. 1782, doi. 10.1111/1759-7714.12894

By:

Kanazu, Masaki;
Edahiro, Ryuya;
Krebe, Hiroyuki;
Nishida, Kohei;
Ishijima, Mikako;
Uenami, Takeshi;
Akazawa, Yuki;
Yano, Yukihiro;
Yamaguchi, Toshihiko;
Mori, Masahide

Publication type:

Article

Case series of pleomorphic carcinomas of the lung treated with nivolumab.

Published in:

Thoracic Cancer, 2017, v. 8, n. 6, p. 724, doi. 10.1111/1759-7714.12505

By:

Kanazu, Masaki;
Uenami, Takeshi;
Yano, Yukihiro;
Nakatsubo, Saeko;
Hosono, Yuki;
Ishijima, Mikako;
Akazawa, Yuki;
Yamaguchi, Toshihiko;
Urasaki, Koji;
Mori, Masahide;
Yokota, Soichiro

Publication type:

Article

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.

Published in:

2020

By:

Morita, Mitsunori;
Tamiya, Motohiro;
Fujimoto, Daichi;
Tamiya, Akihiro;
Suzuki, Hidekazu;
Hirano, Katsuya;
Fukuda, Yasushi;
Yokoyama, Toshihide;
Kominami, Ryota;
Kanazu, Masaki;
Uchida, Junji;
Hara, Satoshi;
Yamashita, Shuji;
Tomioka, Hiromi

Publication type:

journal article

Bronchial ethanol injection therapy for airway obstruction in lung cancer patients.

Published in:

Respirology Case Reports, 2021, v. 9, n. 9, p. 1, doi. 10.1002/rcr2.816

By:

Okabe, Fukuko;
Yano, Yukihiro;
Kuge, Tomoki;
Uenami, Takeshi;
Kanazu, Masaki;
Mori, Masahide

Publication type:

Article

Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).

Published in:

2020

By:

Miura, Satoru;
Yamanaka, Takeharu;
Kato, Terufumi;
Ikeda, Satoshi;
Horinouchi, Hidehito;
Ichihara, Eiki;
Kanazu, Masaki;
Takiguchi, Yuichi;
Tanaka, Kentaro;
Goto, Yasuhiro;
Sata, Masafumi;
Hagiwara, Koichi;
Okamoto, Hiroaki;
Tanaka, Hiroshi

Publication type:

journal article

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Published in:

2020

By:

Hosoya, Kazutaka;
Fujimoto, Daichi;
Morimoto, Takeshi;
Kumagai, Toru;
Tamiya, Akihiro;
Taniguchi, Yoshihiko;
Yokoyama, Toshihide;
Ishida, Tadashi;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Kominami, Ryota;
Tomii, Keisuke;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Uchida, Junji;
Morita, Mitsunori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Makio, Takeshi;
Hara, Satoshi

Publication type:

journal article

Early pharmacodynamic assessment using (18)f-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.

Published in:

2014

By:

Kanazu, Masaki;
Maruyama, Kaoru;
Ando, Masahiko;
Asami, Kazuhiro;
Ishii, Mari;
Uehira, Kazutaka;
Minomo, Shojiro;
Matsuda, Yoshinobu;
Kawaguchi, Tomoya;
Atagi, Shinji;
Ogawa, Yoji;
Kusunoki, Yoko;
Takada, Minoru;
Kubo, Akihito

Publication type:

Journal Article

Early Pharmacodynamic Assessment Using <sup>18</sup>F-Fluorodeoxyglucose Positron-Emission Tomography on Molecular Targeted Therapy and Cytotoxic Chemotherapy for Clinical Outcome Prediction.

Published in:

Clinical Lung Cancer, 2014, v. 15, n. 3, p. 182, doi. 10.1016/j.cllc.2014.01.001

By:

Masaki Kanazu;
Kaoru Maruyama;
Masahiko Ando;
Kazuhiro Asami;
Mari Ishii;
Kazutaka Uehira;
Shojiro Minomo;
Yoshinobu Matsuda;
Tomoya Kawaguchi;
Shinji Atagi;
Yoji Ogawa;
Yoko Kusunoki;
Minoru Takada;
Akihito Kubo

Publication type:

Article

Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors.

Published in:

Oncology Letters, 2017, v. 14, n. 6, p. 7589, doi. 10.3892/ol.2017.7125

By:

Yoshihiko Taniguchi;
Akihiro Tamiya;
Kenji Nakahama;
Yoko Naoki;
Masaki Kanazu;
Naoki Omachi;
Kyoichi Okishio;
Takahiko Kasai;
Shinji Atagi

Publication type:

Article

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

Published in:

PLoS ONE, 2019, v. 14, n. 7, p. 1, doi. 10.1371/journal.pone.0220570

By:

Ryuya Edahiro;
Masaki Kanazu;
Hiroyuki Kurebe;
Masahide Mori;
Daichi Fujimoto;
Yoshihiko Taniguchi;
Hidekazu Suzuki;
Katsuya Hirano;
Toshihide Yokoyama;
Mitsunori Morita;
Yasushi Fukuda;
Junji Uchida;
Takeshi Makio;
Motohiro Tamiya

Publication type:

Article

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.

Published in:

PLoS ONE, 2018, v. 13, n. 8, p. 1, doi. 10.1371/journal.pone.0203070

By:

Yano, Yukihiro;
Kurebe, Hiroyuki;
Edahiro, Ryuya;
Hosono, Yuki;
Nakatsubo, Saeko;
Nishida, Kohei;
Sawa, Nobuyuki;
Ishijima, Mikako;
Uenami, Takeshi;
Kanazu, Masaki;
Akazawa, Yuki;
Yamaguchi, Toshihiko;
Mori, Masahide

Publication type:

Article

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer.

Published in:

Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-54804-9

By:

Nakao, Keiko;
Kobuchi, Shinji;
Marutani, Shuhei;
Iwazaki, Ayano;
Tamiya, Akihiro;
Isa, Shunichi;
Okishio, Kyoichi;
Kanazu, Masaki;
Tamiya, Motohiro;
Hirashima, Tomonori;
Imai, Kimie;
Sakaeda, Toshiyuki;
Atagi, Shinji

Publication type:

Article

Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.

Published in:

JAMA Network Open, 2023, v. 6, n. 2, p. e230698, doi. 10.1001/jamanetworkopen.2023.0698

By:

Fujimoto, Daichi;
Morimoto, Takeshi;
Tamiya, Motohiro;
Hata, Akito;
Matsumoto, Hirotaka;
Nakamura, Atsushi;
Yokoyama, Toshihide;
Taniguchi, Yoshihiko;
Uchida, Junji;
Sato, Yuki;
Yokoi, Takashi;
Tanaka, Hisashi;
Furuya, Naoki;
Masuda, Takeshi;
Sakata, Yoshihiko;
Miyauchi, Eisaku;
Hara, Satoshi;
Saito, Go;
Miura, Satoru;
Kanazu, Masaki

Publication type:

Article

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

Published in:

2018

By:

Kaneda, Toshihiko;
Yoshioka, Hiroshige;
Tamiya, Motohiro;
Tamiya, Akihiro;
Hata, Akito;
Okada, Asukaka;
Niwa, Takashi;
Shiroyama, Takayuki;
Kanazu, Masaki;
Ishida, Tadashi;
Katakami, Nobuyuki

Publication type:

journal article

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 361, doi. 10.1007/s10637-021-01203-5

By:

Tamiya, Motohiro;
Fujikawa, Kei;
Suzuki, Hidekazu;
Yokoyama, Toshihide;
Uenami, Takeshi;
Tamiya, Akihiro;
Sato, Yuki;
Saito, Go;
Uchida, Junji;
Morita, Mitsunori;
Hirashima, Tomonori;
Fukuda, Yasushi;
Kanazu, Masaki;
Hosoya, Kazutaka;
Suzuki, Takuji;
Ueno, Kiyonobu;
Fujimoto, Daichi;
Kumagai, Toru;
Teramukai, Satoshi

Publication type:

Article

Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.

Published in:

Investigational New Drugs, 2021, v. 39, n. 3, p. 853, doi. 10.1007/s10637-020-01060-8

By:

Sugimoto, Takeya;
Fujimoto, Daichi;
Sato, Yuki;
Tamiya, Motohiro;
Yokoi, Takashi;
Tamiya, Akihiro;
Iwasawa, Shunichiro;
Hata, Akito;
Uchida, Junji;
Fukuda, Yasushi;
Hara, Satoshi;
Kanazu, Masaki;
Hirano, Katsuya;
Kokubo, Masaki;
Yamamoto, Nobuyuki

Publication type:

Article

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

Published in:

Investigational New Drugs, 2020, v. 38, n. 1, p. 211, doi. 10.1007/s10637-019-00882-5

By:

Kawachi, Hayato;
Tamiya, Motohiro;
Tamiya, Akihiro;
Ishii, Seigo;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Fukuda, Yasushi;
Yokoyama, Toshihide;
Kominami, Ryota;
Fujimoto, Daichi;
Hosoya, Kazutaka;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Uchida, Junji;
Morita, Mitsunori;
Makio, Takeshi;
Hara, Satoshi;
Kumagai, Toru

Publication type:

Article

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Published in:

Investigational New Drugs, 2019, v. 37, n. 6, p. 1266, doi. 10.1007/s10637-019-00843-y

By:

Tamiya, Motohiro;
Tamiya, Akihiro;
Hosoya, Kazutaka;
Taniguchi, Yoshihiko;
Yokoyama, Toshihide;
Fukuda, Yasushi;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Kominami, Ryota;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Uchida, Junji;
Morita, Mitsunori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Kinoshita, Yoshinori;
Hara, Satoshi;
Kumagai, Toru;
Fujimoto, Daichi

Publication type:

Article

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

Published in:

2021

By:

Hosoya, Kazutaka;
Fujimoto, Daichi;
Morimoto, Takeshi;
Kumagai, Toru;
Tamiya, Akihiro;
Taniguchi, Yoshihiko;
Yokoyama, Toshihide;
Ishida, Tadashi;
Matsumoto, Hirotaka;
Hirano, Katsuya;
Kominami, Ryota;
Tomii, Keisuke;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Tanaka, Satoshi;
Uchida, Junji;
Morita, Mitsunori;
Kanazu, Masaki;
Mori, Masahide;
Nagata, Kenji

Publication type:

journal article